Literature DB >> 22221970

Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011.

H Ardeschir Ghofrani1, Oliver Distler, Felix Gerhardt, Matthias Gorenflo, Ekkehard Grünig, Walter E Haefeli, Matthias Held, Marius M Hoeper, Christian M Kähler, Harald Kaemmerer, Hans Klose, Volker Köllner, Bruno Kopp, Siegrun Mebus, Andreas Meyer, Oliver Miera, David Pittrow, Gabriela Riemekasten, Stephan Rosenkranz, Dietmar Schranz, Robert Voswinckel, Horst Olschewski.   

Abstract

The 2009 European Guidelines on Diagnosis and Treatment of Pulmonary Hypertension have been adopted for Germany. The guidelines contain detailed recommendations on the diagnosis of pulmonary hypertension (PH). However, the practical implementation of the European Guidelines in Germany requires the consideration of several country-specific issues and already existing novel data. This requires a detailed commentary to the guidelines, and in some aspects an update already appears necessary. In June 2010, a Consensus Conference organized by the PH working groups of the German Society of Cardiology (DGK), the German Society of Respiratory Medicine (DGP) and the German Society of Pediatric Cardiology (DGPK) was held in Cologne, Germany. This conference aimed to solve practical and controversial issues surrounding the implementation of the European Guidelines in Germany. To this end, a number of working groups was initiated, one of which was specifically dedicated to the treatment of pulmonary arterial hypertension (PAH). This commentary describes in detail the results and recommendations of the working group on treatment of PAH which were last updated in October 2011.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 22221970     DOI: 10.1016/S0167-5273(11)70490-9

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  10 in total

1.  Ventricular tachycardias in patients with pulmonary hypertension: an underestimated prevalence? A prospective clinical study.

Authors:  Dirk Bandorski; D Erkapic; J Stempfl; R Höltgen; E Grünig; J Schmitt; R Chasan; J Grimminger; T Neumann; C W Hamm; W Seeger; H A Ghofrani; H Gall
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2015-06-02

2.  Intratracheal administration of cyclooxygenase-1-transduced adipose tissue-derived stem cells ameliorates monocrotaline-induced pulmonary hypertension in rats.

Authors:  Naveen K Somanna; Philipp M Wörner; Subramanyam N Murthy; Edward A Pankey; Deborah J Schächtele; Rose-Claire St Hilaire; David Jansen; Abigail E Chaffin; Bobby D Nossaman; Eckhard U Alt; Philip J Kadowitz; Reza Izadpanah
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-08-22       Impact factor: 4.733

3.  Medical treatment of pulmonary hypertension in adults with congenital heart disease: updated and extended results from the International COMPERA-CHD Registry.

Authors:  Christian Opitz; Ekkehard Grünig; Stephan Rosenkranz; Ann-Sophie Kaemmerer; Matthias Gorenflo; Dörte Huscher; David Pittrow; Peter Ewert; Christine Pausch; Marion Delcroix; Hossein A Ghofrani; Marius M Hoeper; Rainer Kozlik-Feldmann; Andris Skride; Gerd Stähler; Carmine Dario Vizza; Elena Jureviciene; Dovile Jancauskaite; Lina Gumbiene; Ralf Ewert; Ingo Dähnert; Matthias Held; Michael Halank; Dirk Skowasch; Hans Klose; Heinrike Wilkens; Katrin Milger; Christian Jux; Martin Koestenberger; Laura Scelsi; Eva Brunnemer; Michael Hofbeck; Silvia Ulrich; Anton Vonk Noordegraaf; Tobias J Lange; Leonhard Bruch; Stavros Konstantinides; Martin Claussen; Judith Löffler-Ragg; Hubert Wirtz; Christian Apitz; Rhoia Neidenbach; Sebastian Freilinger; Attila Nemes
Journal:  Cardiovasc Diagn Ther       Date:  2021-12

4.  Comparison of Healthcare Encounters and Drug Persistence in Patients With Pulmonary Arterial Hypertension Receiving Oral Selexipag, Inhaled Iloprost, or Parenteral Treprostinil: A Retrospective Database Analysis.

Authors:  Ci Song; Peter Kunovszki; Amélie Beaudet
Journal:  J Health Econ Outcomes Res       Date:  2022-06-08

5.  Platelet abnormalities in chronic thromboembolic pulmonary hypertension.

Authors:  Anna Remková; Iveta Šimková; Tatiana Valkovičová
Journal:  Int J Clin Exp Med       Date:  2015-06-15

6.  The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases.

Authors:  Ghazwan Butrous
Journal:  Glob Cardiol Sci Pract       Date:  2014-10-16

7.  Pulmonary Hypertension: Scientometric Analysis and Density-Equalizing Mapping.

Authors:  Michael Götting; Mario Schwarzer; Alexander Gerber; Doris Klingelhöfer; David A Groneberg
Journal:  PLoS One       Date:  2017-01-04       Impact factor: 3.240

8.  Sexual health and health-related quality of life among women with pulmonary arterial hypertension.

Authors:  Debasree Banerjee; Sara E Vargas; Kate M Guthrie; Brittany M Wickham; Melissa Allahua; Mary E Whittenhall; Amy J Palmisciano; Corey E Ventetuolo
Journal:  Pulm Circ       Date:  2018 Oct-Dec       Impact factor: 3.017

9.  Treatment with anti-gremlin 1 antibody ameliorates chronic hypoxia/SU5416-induced pulmonary arterial hypertension in mice.

Authors:  Loredana Ciuclan; Kellyann Sheppard; Liqun Dong; Daniel Sutton; Nicholas Duggan; Martin Hussey; Jenny Simmons; Nicholas W Morrell; Gabor Jarai; Matthew Edwards; Gerald Dubois; Matthew Thomas; Gino Van Heeke; Karen England
Journal:  Am J Pathol       Date:  2013-11       Impact factor: 4.307

10.  Pulmonary hypertension in Portugal: first data from a nationwide registry.

Authors:  Rui Baptista; José Meireles; Ana Agapito; Graça Castro; António Marinho da Silva; Teresa Shiang; Fabienne Gonçalves; Susana Robalo-Martins; António Nunes-Diogo; Abílio Reis
Journal:  Biomed Res Int       Date:  2013-10-21       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.